Black Diamond Therapeutics Inc (BDTX)

[FACT-MASTER]

That is true to a certain point.

imo, the addition of cohort 3 sort of leans the P1 data to being positive. We know that Temozolomide is an older therapy with limited results. The question remains though, what did they find in the cohort 1 and 2 that precipitated cohort 3 - could be interesting.

I'm sure BDTX mgmt.is aware of what Nimbus was able to do with their P1 results from their psoriasis therapeutic. 1535 for NSCLC / GBM is a much more serious illness, however i concur, it would all depend on how good P1 data is for someone, say Merck for example, to step up, ante up, and continue 1535 development.